Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report. - Chandra S; Hansraj S; Adhikari A; Ponvilawan B; Tolentino A; Bansal D (Frontiers in oncology, 2026)